Logo
Homepage
Explore Our Models
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Antibody Therapy CRO Services
Cyagen provides comprehensive CRO services for antibody therapy development. Our platform supports you from discovery to validation, leveraging fully human antibody mouse models and cutting-edge AI tools to significantly accelerate your therapeutic breakthroughs.
A Next-Gen Antibody R&D Engine
Our HUGO-Ab™ platform includes three validated product lines – HUGO-Mab™, HUGO-Light™, and HUGO-Nano™ – supported by flexible licensing or co-development models. Whether your goal is monoclonal, bispecific, or nanobody discovery, we offer a comprehensive, data-backed solution from target immunization to in vivo efficacy testing.
{{ item.title }}
{{static_tabs[0].title}}
HUGO-Mab™ – Fully Human Monoclonal Antibody Mice
Generate. Diversify. Translate.
Our next-generation HUGO-Mab™ mice are designed to express fully human immunoglobulin variable regions across both heavy and light chains. These models recapitulate native immune development and B cell selection processes, enabling the in vivo generation of high-affinity, human-sequence monoclonal antibodies. Ideal for developing therapeutic antibodies with broad epitope coverage, HUGO-Mab™ mice offer validated performance across diverse antigen targets and preclinical validation settings.
Figure 1. Schematic of antibody gene structure in HUGO-Mab™ mice, showing full human VH, VK, and VL regions.
Key Features
  • Complete humanization of VH, VK, and VL loci
  • Multiple strains: C57BL/6, BALB/c, SJL available
  • Expresses all human antibody V genes for broad diversity
  • Maintains ADCC/CDC functionality via native constant regions
Inquire About Licensing
Validation Highlights
Our fully human monoclonal antibody mice exhibit robust immune development, diverse antibody repertoires, and proven in vivo efficacy.
Figure 2. Growth curve demonstrating development consistency with WT mice.
Figure 3. Heavy chain VDJ recombination in naïve B cells reflects rich sequence diversity.
Figure 4. Kappa light chain VJ recombination patterns align with human profiles.
Figure 5. Lambda light chain VJ recombination confirms repertoire breadth.
Figure 6. CDR3 length distribution matches expected human antibody diversity.
Figure 7. Normal immune cell composition in spleen, matching WT profiles.
Figure 8. Comparable serum titers after immunization with multiple antigens.
Figure 9. High-affinity binding to PD-L1 validated via kinetic assays.
Figure 10. T cell activation in MLR assays confirms functional antibody production.
Figure 11. In vivo tumor suppression in humanized mouse model.
{{static_tabs[1].title}}
HUGO-Light™ – Human Common Light Chain Mice
Simplify Pairing. Enable Bispecifics.
HUGO-Light™ mice are engineered with fixed human VK light chains to streamline the production of common light chain antibodies – a critical requirement for bispecific antibody formats. By minimizing light-heavy chain pairing complexity, these models reduce downstream screening burden while maintaining robust immunogenicity and high serum titers. With 10 validated strains expressing distinct VK variants, HUGO-Light™ provides a powerful in vivo system for rapid bispecific pipeline advancement.
Figure 1. Schematic of antibody gene structure in HUGO-Light™ mice with fixed human VK and knocked-out mouse light chain loci.
Key Features
  • Fixed human VK light chain (8 mono- and 2 multi-gene variants)
  • Compatible with full human VH diversity
  • Excellent serum titers post-immunization
  • Dual background availability: C57BL/6 and BALB/c
Available Product Variants
  • 10 total strains (8 mono-gene VK + 2 multi-gene VK)
  • All models constructed using ES cell targeting on C57BL/6NCya background
  • Mouse lambda chains knocked out and fixed human kappa chains inserted
Download Full Variant Table (PDF) >> Ask About Dual-Target Projects >>
Validation Highlights
Explore the immune performance and functional validation of our 10 engineered common light chain mouse models.
Figure 2. VDJ diversity of heavy chain in naïve splenic B cells.
Figure 3. Balanced immune cell profiles in both spleen and blood.
Figure 4. Strong serum antibody titers post-immunization.
Figure 5. Microfluidic B-cell screening supports high-throughput hit discovery.
Figure 6. ELISA confirms binding activity of selected anti-VEGF165 clones.
{{static_tabs[2].title}}
HUGO-Nano™ – Fully Human Nanobody Mice
Go Smaller. Target Deeper.
HUGO-Nano™ mice are specially engineered to produce fully human, heavy-chain-only antibodies—ideal for generating nanobody therapeutics with enhanced tissue penetration, thermal stability, and solubility. This platform enables the development of compact, high-specificity binders suitable for CNS targets, intracellular epitopes, or modular bispecific designs. The reduced size and unique structure of nanobodies produced from HUGO-Nano™ open new possibilities in antibody engineering and drug delivery.
Key Features
  • Fully human heavy-chain-only antibody generation
  • Compact and modular antibody format
  • Suitable for CNS delivery, tumor penetration, or bispecific applications
  • TurboKnockout® engineered for genomic precision and stability
Inquire About Licensing
Validation Highlights
Compact, high-penetration antibody formats start here—backed by sequence fidelity and in vitro activity
Figure 1. VDJ rearrangement confirms CH1 deletion and nanobody diversity.
Figure 2. Normal lymphocyte subsets in peripheral blood.
Figure 3. ELISA shows strong PD-L1 binding affinity of nanobodies.
{{static_tabs[3].title}}
AbSeek™ – Intelligent Antibody Discovery Platform
Predict. Optimize. Accelerate.
AbSeek™ combines bioinformatics, machine learning, and structural modeling to empower rational antibody discovery and sequence refinement. From simulating VDJ recombination and antigen-binding prediction to optimizing developability properties, AbSeek™ integrates seamlessly with Cyagen’s in vivo platforms. It enables rapid design-build-test cycles, significantly shortening timelines for lead identification and candidate optimization.
Capabilities Include:
  • VDJ recombination simulation
  • Structural modeling and binding prediction
  • Sequence optimization for affinity, stability, and developability
  • Seamless integration with wet-lab validation
Try AbSeek™ In Your Next Project >> Book a Free Consultation >>
{{static_tabs[4].title}}
Supporting Capabilities for Antibody Validation
Enhance. Confirm. Translate.
Cyagen supports your antibody discovery from bench to in vivo validation. Our immunization services offer flexible antigen formats, tailored adjuvants, and multi-route delivery strategies to maximize immune response. We also provide comprehensive efficacy validation via tumor inhibition, immune profiling, and cytokine assays – ensuring that your lead candidates are functionally robust and translationally relevant.
Capability Description
Custom Immunization & B-Cell Screening Tailored immunization protocols for peptides or proteins, combined with single B-cell screening to identify high-affinity, fully human antibodies.
In Vivo Functional Validation PBMC-humanized tumor models, cytokine profiling, and flow cytometry-based analysis to confirm therapeutic efficacy and immune response.
Our Unique Advantages
Fully Human Antibody Generation
Access three fully validated antibody platforms to generate high-affinity, fully human antibodies for a wide range of therapeutic applications.
Comprehensive In-House Validation
Benefit from rigorous in vivo and in vitro validation, ensuring reliable efficacy and stability for your antibody candidates.
Flexible Engagement Models
Choose from licensing or co-development options that best suit your project's needs and intellectual property goals.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Inquiry Details
Main Area of Research
Service(s) of Interest
Project Details
Contact Information
Full Name
Email
Phone Number
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest